News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-148

No the last thing they need is a CR , it will just piss of existing shareholders and crash the SP before they can even get it up . The directors NEED to cut deals to partner one or more products preferably with a major US company that has clout in the FDA . This would hopefully give AHZ a large cash injection and leave the cost of further. development of the project in someone else’s hands . The directors need to do what they are paid to do , so far they have done a crap job and keep on diluting everyone’s shareholding while continuing R@D on to many products without achieving the approvals or sales needed to maintain the companies capital base . The directors need to man up and fix the mess they created